Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

NCT05575518 is registered in ClinicalTrials.gov with Stellah Mpagama as lead sponsor.

NCT NCT05575518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05575518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Lead sponsor
Stellah Mpagama
Phase
Phase 3
Overall status
Unknown status
Start date
August 11, 2023
Completion date
March 31, 2026
Enrollment
414 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus, tuberculosis